What a difference a day makes.
Yesterday Boston Scientific Corp. was fielding false claims and Medicare fraud charges.
The 38-mm paclitaxel-eluting stent, which the company touts as the longest on the market, won CE Mark approval from the European Union in 2007. It’s designed to treat long vascular lesions that usually require surgeons to use stents.
And Standard & Poor’s said BSC could be getting even more good news soon, according to the Wall Street Journal (subscription).
That’s because the rating service is poised to upgrade BoSci from junk bond status to investment grade. If it happens, it would be the company’s latest step back from its slide into fallen angel status as it pays down a vast debt load.